$0.20
0.00%
Nasdaq, Wed, Oct 15 2025
ISIN
CA29668H7085
Symbol
EPIX

ESSA Pharma Inc Stock price

$0.20
+0.01 4.63% 1M
-1.43 87.66% 6M
-1.59 88.76% YTD
-5.75 96.62% 1Y
-1.77 89.79% 3Y
-6.55 97.02% 5Y
-131.76 99.85% 10Y
-88.11 99.77% 20Y
Nasdaq, Closing price Wed, Oct 15 2025
+0.00 0.00%
ISIN
CA29668H7085
Symbol
EPIX
Industry

Key metrics

Basic
Market capitalization
$9.5m
Enterprise Value
$-100.1m
Net debt
positive
Cash
$109.6m
Shares outstanding
44.4m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
4.8
P/B
0.1
Financial Health
Equity Ratio
97.7%
Return on Equity
-22.8%
ROCE
-27.2%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-29.6m | -
EBIT
$-29.7m | $-33.6m
Net Income
$-25.1m | $-32.2m
Free Cash Flow
$-20.9m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
12.5% | -
EBIT
12.5% | 2.5%
Net Income
9.2% | -12.7%
Free Cash Flow
12.4%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-0.6
FCF per Share
$-0.5
Short interest
3.6%
Employees
35
Rev per Employee
$0.0
Show more

Is ESSA Pharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

ESSA Pharma Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a ESSA Pharma Inc forecast:

4x Hold
57%
3x Sell
43%

Analyst Opinions

7 Analysts have issued a ESSA Pharma Inc forecast:

Hold
57%
Sell
43%

Financial data from ESSA Pharma Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs 0.06 0.06
25% 25%
-
-0.06 -0.06
25% 25%
-
- Selling and Administrative Expenses 17 17
45% 45%
-
- Research and Development Expense 13 13
43% 43%
-
-30 -30
13% 13%
-
- Depreciation and Amortization 0.09 0.09
29% 29%
-
EBIT (Operating Income) EBIT -30 -30
12% 12%
-
Net Profit -25 -25
9% 9%
-

In millions USD.

Don't miss a Thing! We will send you all news about ESSA Pharma Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ESSA Pharma Inc Stock News

Neutral
PRNewsWire
7 days ago
SOUTH SAN FRANCISCO, Calif., USA and VANCOUVER, BC, Canada , Oct. 9, 2025 /PRNewswire/ - ESSA Pharma Inc. (NASDAQ: EPIX) ("ESSA" or the "Company") today announced the completion of XenoTherapeutics' ("Xeno") previously announced acquisition of ESSA (the "Acquisition").
Neutral
PRNewsWire
9 days ago
SOUTH SAN FRANCISCO, USA and VANCOUVER, Canada , Oct. 6, 2025 /PRNewswire/ - ESSA Pharma Inc. (NASDAQ: EPIX) ("ESSA" or the "Company") is pleased to announce that its Securityholders (as defined below) have approved the acquisition of all of the issued and outstanding common shares of the Company (the "Common Shares" and the holders of such Common Shares, the "Shareholders") by XenoTherapeutics...
Neutral
Seeking Alpha
12 days ago
ESSA Pharma Inc. (NASDAQ:EPIX ) Shareholder/Analyst Call October 3, 2025 5:00 PM EDT Company Participants David Parkinson - President, CEO & Director David Wood - Chief Financial Officer Conference Call Participants Dave Bains Presentation Operator Hello, and welcome to the Special Meeting of Security Holders of ESSA Pharma, Inc. Please note that the meeting is being recorded. I'd like to intro...
More ESSA Pharma Inc News

Company Profile

ESSA Pharma, Inc. engages in the development of small molecule drugs for prostate cancer. It focuses on producing drugs which selectively block the amino-terminal domain (NTD) of the androgen receptor (AR), potentially overcoming the known AR-dependent resistance mechanisms of castration-resistant prostate cancer (CRPC), and providing CRPC patients with the potential for increased progression-free and overall survival. The company was founded by Marianne D. Sadar and Raymond J. Andersen on January 6, 2009 and is headquartered in Vancouver, Canada.

Head office Canada
CEO David Parkinson
Employees 35
Founded 2009
Website www.essapharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today